T 0136/24 (Cabazitaxel / SANOFI) of 03.06.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T013624.20250603
- Date of decision
- 3 June 2025
- Case number
- T 0136/24
- Petition for review of
- -
- Application number
- 10782039.1
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on Article 056 EPC
- Application title
- Novel antitumoral use of cabazitaxel
- Applicant name
- SANOFI
- Opponent name
- Glenmark Pharmaceuticals Europe Ltd
Accord Healthcare Ltd
Zentiva k.s.
Fresenius Kabi Deutschland GmbH
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
Generics (U.K.) Limited
Vossius & Partner Patentanwälte Rechtsanwälte mbB
STADA Arzneimittel AG
Maiwald GmbH
Accord Healthcare S.L.U. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 113(1)European Patent Convention Art 54(2)European Patent Convention Art 54(5)European Patent Convention Art 56European Patent Convention Art 87European Patent Convention R 103(1)(a)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Grounds for opposition - do not prejudice maintenance of the patent
- Catchword
- On the issue of reasonable expectation of success in view of (announcements of) clinical studies in the prior art, see Reasons 7.14 to 7.14.10
- Cited cases
- T 0158/96T 1009/97T 2506/12T 1491/14T 0239/16T 0072/18T 1806/18T 2344/19T 2963/19T 3165/19T 0096/20T 1045/21T 1437/21T 1941/21
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed.